Bullboard - Stock Discussion Forum Waverley Pharma Inc V.WAVE

Healthcare Biotechnology

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. Its primary focus is the PARP-1 program and secondary focus is the generic oncology injectable market in European Union, the United Kingdom (UK) and North America. It has entered into a license, manufacture, supply, marketing and distribution... see more

Add To Watchlist

TSXV:WAVE - Post Discussion

Waverley Pharma Inc > Revenue from UK's NHS alone should be a big boost.

View:

Post by Horn1369 on Aug 04, 2020 1:11pm

Revenue from UK's NHS alone should be a big boost.

For the share price. We should see the numbers from EU in next Qs. GL

Products:

Waverley Pharma Inc. has a collaboration with Reliance Life Sciences Private Limited (RLS) part of a conglomerate based in Mumbai, India, for the commercialization of a number of oncology drugs for the United States and European markets.

Drugs for sale in Europe:

Capecitabine:Capecitabine is manufactured by RLS, and the binding contracts with the UK National Health Service for the supply of capecitabine have been transferred to Waverley Pharma. The product is approved in Germany and Waverley Pharma is seeking a sales and marketing partner.

Temozolomide: Temozolomide is manufactured by RLS, and the binding contracts with the UK National Health Service for the supply of temozolomide have been transferred to Waverley pharma.

Erlotinib: Erlotinib is manufactured by RLS. Waverley Pharma has a binding contract with the U.K. National Health Service for the supply of Erlotinib.

How much money does the NHS spend on cancer?

Expenditure on cancer servicesIn nominal terms (the amount of money spent each year), spending had increased by 40% from £69.7 billion to £94.8 billion.

159